We are a Canadian-based technology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.
The Company was formed in 2001 to study the genetic mechanisms of biofilm formation, which has led to the discovery of novel compounds that inhibit or disrupt biofilms.
To be a global leader in creating innovative technologies for licensing and product commercialization that breakdown and disperse biofilms.
To discover and commercialize unique and compelling technologies that will prevent biofilm related infections in human and animal healthcare as well as biofilm related problems in industrial applications.
Medtec Models & Misfires Webinar
Antimicrobial Stewardship and Biofilms: Research Opportunities
2019 Business Update
Kane Biotech is a discovery and development company focused on novel products that prevent and disperse bacterial biofilms. Kane was formed to translate these discoveries into innovative solutions for human and animal health, as well as industrial applications. Kane’s commercial strategy is to create value for shareholders through the establishment of global partnerships and licensing agreements with leading companies to commercialize our innovations. To de-risk our technologies towards commercialization we will conduct more advanced clinical studies and achieve regulatory and safety certifications.
- Internal discovery of novel technologies that inhibit and disperse biofilms and control microbial infections
- In-licensing of exclusive, novel biofilm technologies: University of Toronto and University of Manitoba – Canada, Rutgers University – USA
- Develop and test prototypes
- Conduct pre-clinical performance tests
- Examine durability, stability and biocompatibility
- Joint development agreements or partner assisted clinical trials
- Partnerships or licensing agreements are developed with leading companies to manufacture and commercialize products.
- Test products for market acceptance and create brands for market launch.
Meet the people behind Kane Biotech.
Chief Executive Officer
Mr. Edwards is the founder and President of VetRx, a Montreal-based technology company specializing in data collection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. Mr. Edwards holds a Bachelor’s degree (Finance) from l’Université de Sherbrooke and an MBA from Concordia University.
Chief Financial Officer
Ray Dupuis joined Kane Biotech as Chief Financial Officer in September 2017. Mr. Dupuis has more than 25 years of financial leadership experience across a broad range of industries including 15 years at a rapidly growing public biotechnology company and brings to the organization considerable financial acumen and strategic skills. Mr. Dupuis is a Chartered Professional Accountant (CPA, CGA) and possesses Bachelor of Science (Biology), Bachelor of Arts (Administrative Studies) and Master of Business Administration (Finance) degrees.
Dr. Nanda Yakandawala
Vice President, Research & Development
Nanda Yakandawala joined Kane Biotech in 2003 and leads the Company’s research efforts. Originally graduating with his B.Sc. from the University of Peradeniya in Sri Lanka, Dr. Yakandawala completed his M.Sc. in biotechnology at the University of Adelaide in Australia followed by his Ph.D. in molecular biology at the Swiss Federal Institute in Zurich. Dr. Yakandawala is a recognized expert in biofilms and is widely published in his field.
Wendy Nachtigall joined Kane Biotech in October 2015 as Director, Retail. With 15+ years in the marketing communications industry, Ms. Nachtigall brings a wealth of knowledge and expertise in planning, implementing and evaluating strategic marketing and communications initiatives in the consumer, institutional and B2B sectors, including new product and service introductions, brand development strategies and growth of business. Ms. Nachtigall has a proven track record in project management, as well as developing and maintaining long-term business relationships.
VP, Quality & Compliance
Lori Christofalos joined Kane Biotech as VP, Quality & Compliance in August 2019. Ms. Christofalos has over 25 years of leadership experience in Quality, Compliance, Validation and Regulatory Affairs in regulated Pharma industry in both domestic and international domains. In addition to this she brings to the organization extensive knowledge of Strategic Planning and process development. Ms. Christofalos has served on Industry boards, is a member of ASQ and holds a Bachelor of Science (Chemistry) and a diploma in Bioengineering-Chemical Technology.
Scientific Advisory Board
Dr. Gordon Guay
Chief Scientific Officer
Dr. Gordon Guay has over twenty-five years of experience in R&D and new product development. He has worked as a Research Fellow at Proctor and Gamble serving as the lead scientist within a range of different P&G business units including: Oral-B, Gillette, Olay, Right Guard, CoverGirl, Max Factor and Duracell. Gordon has received over 11 international awards for new products developed while he is working at P&G. Prior to P&G, Gordon was the Director of Research at Catalytic Antibodies Inc. Gordon received a Ph.D. in molecular genetics from the University of Illinois. His research focused on bacterial resistance to sulfonamides. He also conducted post-Doctoral work at Lederle Laboratories on substrate specificity of tetracycline efflux pumps.
Rivka (Rashieda) Gluck
Scientific Advisory Board Member
Ms. Gluck currently serves as Senior Vice President of Global Clinical Operations at Aurinia Pharmaceuticals Inc. since February 2018 and has also served as its Vice President of Clinical Operations since January 1, 2016. She previously served as Vice President of Clinical Operations at Qu Biologics Inc., where she led the clinical development of their platform immunotherapeutic treatments. Prior to that, Ms. Gluck served as Vice President and Head of Global Clinical Operations at Vifor Pharmaceuticals, based in Zurich Switzerland post acquisition of Aspreva Pharmaceuticals where she was Vice President of Clinical Operations. In her career, Ms. Gluck served in increasingly senior positions at major pharmaceutical companies including Novartis, Organon, and GSK. Ms. Gluck holds a B.Sc. in Nursing from the University of British Columbia.
Dr. Robert Huizinga
Scientific Advisory Board Member
Dr. Huizinga is the Executive Vice-President of Aurinia Pharmaceuticals Inc. Prior to this, he was the VP, Clinical Affairs for Isotechnika from 2002-2013. He has been involved in more than 80 clinical trials from Phase I through Phase IV and the successful development of numerous compounds. Dr. Huizinga holds a PhD in Organizational Leadership, a Masters in Clinical Epidemiology, holds his Nephrology certification and is a member of Sigma Theta Tau. He holds a certificate in leadership from EQUIP Leadership.
Board of Directors
Mr. Edwards was appointed as the President and CEO of the Corporation on September 10, 2018. He is the founder and President of VétRx Inc., a Montreal-based technology company specializing in data collection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. Mr. Edwards holds a bachelor’s degree (Finance) from l’Université de Sherbrooke and an MBA from Concordia University.
Mr. Mark Nawacki is currently the President & CEO of Searchlight Pharma Inc., a Canadian-based specialty pharmaceutical company focused on the acquisition and commercialization of innovative and unique healthcare and pharmaceutical products. Prior to this, Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin Labs, a leading Canadian specialty pharmaceutical company, from 2003 to 2014. Mr. Nawacki holds a BA in International Relations and Russian and East European Studies from the University of Toronto (Trinity), an MBA also from the University of Toronto, and is a Canadian-designated CPA. He also currently sits on the Board of Intelgenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT).
Board Chair, Director
Mr. Renaud is Chairman, CEO and President of Redecam Group, a global leader in providing highly engineered industrial air pollution control solutions. A graduate of Franklin College of Switzerland with a Bachelor of Arts in international financial management, Mr. Renaud has been instrumental in securing many private equity financings and has an extensive European and North American network. He is a past director of a number of publicly traded companies including Yorbeau Resources Inc., Diagnos Inc., and Sierra Metals Inc., and is on the advisory board of Dundee Sarea.
Mr. Morin is a corporate director who sits on the boards of Strom Spa in Montreal, Immervision Inc. (Chair from 2010 to 2019), la Chamber de sécurité financière (Audit Committee and Chair of the Human Resources Committee), the Montreal Symphony Orchestra (Executive Committee and Chair of the Marketing Committee) and Canadian Tire Jumpstart Charities. As a founding partner of Cossette, Canada’s largest communications group, Mr. Morin was instrumental in the growth of the firm nationally from 1973 until he left the firm in 2009. Mr. Morin holds a BA in Business Administration from Laval University as well as an ICD.D designation from the Institute of Corporate Directors.
Dr. Prichard is the acting Vice President (Research) at Western University. She was at McGill University from 1979-2005 as a professor in the Faculty of Medicine. From 2005-15 she served as Vice President at Baxter Healthcare for Medical Affairs and R&D in the Renal and Specialty Therapeutics business units. She has served as a consultant to several medical device companies, as a board member of a privately held company and is currently the Vice Chair of the McGill University Health Center. She previously served on the Board of Directors of the Corporation from 2014-18.
View our current openings.
Working at Kane
Kane Biotech is always looking for bright, talented, and hard working individuals to add to our high performing team.
If you would like the opportunity to work in an exciting and innovative biotech industry, contact us to see what opportunities we have currently.